# A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

> **NCT01500538** · PHASE2 · TERMINATED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 1 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Eltrombopag and Vorinostat

## Key facts

- **NCT ID:** NCT01500538
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2013-05
- **Final completion:** 2014-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor recruitment rate
- **Last updated:** 2016-02-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500538, "A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01500538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*